Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.

MLA

Di Staso, Rossana, et al. “Is CAR T a Drug or a Therapeutic Pathway? Intention to Treat versus per Protocol Analysis of Real World Studies of CAR-T Cell Therapy in Relapsed Refractory Diffuse Large B Cell Lymphoma.” Blood Cancer Journal, vol. 14, no. 1, Nov. 2024, p. 197. EBSCOhost, https://doi.org/10.1038/s41408-024-01183-8.

APA

Di Staso, R., Casadei, B., Locke, F. L., Jain, M., Voorhees, T. J., Kittai, A. S., Bastos-Oreiro, M., Gutiérrez, A., Martin Garcia-Sancho, A., Terol, M. J., Mead, M., Maranzano, M. J., Iacoboni, G., Barba, P., Kwon, M., Bailen, R., Reguera-Ortega, J. L., Mian, A., Hill, B., … Argnani, L. (2024). Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma. Blood Cancer Journal, 14(1), 197. https://doi.org/10.1038/s41408-024-01183-8

Chicago

Di Staso, Rossana, Beatrice Casadei, Frederick L Locke, Michael Jain, Timothy J Voorhees, Adam S Kittai, Mariana Bastos-Oreiro, et al. 2024. “Is CAR T a Drug or a Therapeutic Pathway? Intention to Treat versus per Protocol Analysis of Real World Studies of CAR-T Cell Therapy in Relapsed Refractory Diffuse Large B Cell Lymphoma.” Blood Cancer Journal 14 (1): 197. doi:10.1038/s41408-024-01183-8.